Anlon Healthcare IPO is a book-built issue worth βΉ121.03 crores, consisting entirely of a fresh issue of 1.33 crore equity shares.
The IPO will open for subscription on August 26, 2025, and close on August 29, 2025. The basis of allotment is expected to be finalized on September 1, 2025, while the shares are likely to be listed on BSE and NSE with a tentative listing date of September 3, 2025.
The price band for Anlon Healthcare IPO is fixed between βΉ86 to βΉ91 per share. The lot size is set at 164 shares, requiring a minimum investment of βΉ14,104 for retail investors. For Non-Institutional Investors, the minimum application size is 14 lots (2,296 shares) amounting to βΉ2,08,936 for sNII and 68 lots (11,152 shares) amounting to βΉ10,14,832 for bNII.
Anlon Healthcare IPO Details
| General | Detail |
|---|---|
| IPO Date | August 26, 2025 to August 29, 2025 |
| Listing Date | [.] |
| Face Value | βΉ10 per share |
| Issue Price Band | βΉ86 to βΉ91 per share |
| Lot Size | 164 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 1,33,00,000 shares (aggregating up to βΉ121.03 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 3,98,51,500 shares |
| Share Holding Post Issue | 5,31,51,500 shares |
Anlon Healthcare IPO Date
Anlon Healthcare IPO will open for subscription on August 26, 2025, and close on August 29, 2025.
| IPO Timeline | Date |
|---|---|
| IPO Open Date | Tue, Aug 26, 2025 |
| IPO Close Date | Fri, Aug 29, 2025 |
| Tentative Allotment | Mon, Sep 1, 2025 |
| Initiation of Refunds | Tue, Sep 2, 2025 |
| Credit of Shares to Demat | Tue, Sep 2, 2025 |
| Tentative Listing Date | Wed, Sep 3, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on August 29, 2025 |
Anlon Healthcare IPO Lot Size
Investors can place bids for a minimum of 164 shares and in multiples thereof. The table below outlines the minimum and maximum investment limits for Individual Retail Investors and High Net-Worth Individuals (HNI) in terms of both number of shares and application amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 164 | βΉ14,924 |
| Retail (Max) | 13 | 2,132 | βΉ1,94,012 |
| S-HNI (Min) | 14 | 2,296 | βΉ2,08,936 |
| S-HNI (Max) | 67 | 10,988 | βΉ9,99,908 |
| B-HNI (Min) | 68 | 11,152 | βΉ10,14,832 |
Anlon Healthcare IPO Promoter Holding
The company is promoted by Punitkumar R. Rasadia, Meet Atulkumar Vachhani, and Mamata Punitkumar Rasadia, who are the key promoters driving the business.
| Share Holding Pre Issue | 70.26% |
| Share Holding Post Issue |
Note: The valuation and ownership impact will be assessed based on Equity Dilution, which is calculated as:
Equity Dilution = Pre-Issue Shareholding β Post-Issue Shareholding
Anlon Healthcare IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not less than 75% of the Net Issue |
| Retail Shares Offered | Not more than 10% of the Net Issue |
| NII Shares Offered | Not Less than 15% of the Net Issue |
About Anlon Healthcare IPO
Anlon Healthcare Ltd. is a Rajkot-based pharmaceutical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. Established in 2013 and commencing production in 2017, the company has built a strong reputation in the bulk drugs segment. Its facility is certified with ISO 9001:2015, GMP, and WHO-GMP, ensuring compliance with global quality standards. The company has steadily expanded its presence across India and exports to more than 15 countries, including Italy, Germany, South Korea, China, Argentina, Chile, Colombia, Mexico, Egypt, Turkey, Japan, Brazil, the UK, and the UAE. The promoters of the company are Punitkumar R. Rasadia, Meet Atulkumar Vachhani, and Mamata Punitkumar Rasadia.
Read More
From a financial standpoint, Anlon Healthcare reported revenue of βΉ66.69 million and profit after tax of βΉ9.66 million in FY24, compared with βΉ113.12 million revenue and βΉ5.82 million profit in FY23, and βΉ57.52 million revenue with a minor loss in FY22. These figures highlight consistent revenue growth and profitability improvement, adding weight to the investment case for the Anlon Healthcare IPO.
The company has positioned itself as a reliable supplier to both domestic and international pharmaceutical players. While specific customer names are not disclosed, its diverse client base and export-driven approach strengthen its credibility. Although detailed market share numbers are not available, its product certifications and growing international reach demonstrate a competitive position. This provides a strong foundation for the upcoming Anlon Healthcare IPO, making it an opportunity investors are keenly watching in the broader IPO market.
Company Products
- Active Pharmaceutical Ingredients (APIs): Wide range of therapeutic segments compliant with pharmacopeia standards (IP, BP, EP, JP, USP).
- Pharmaceutical Intermediates & Key Starting Materials: Used in the production of APIs for regulated and semi-regulated markets.
- Nutraceutical & Intermediate Offerings: Supporting diversification and meeting global demand.
Company Strengths
- Certified Manufacturing Facility: ISO 9001:2015, GMP, and WHO-GMP approvals ensuring high-quality production.
- Research & Development: Equipped with four in-house laboratories for generic API research, process development, and testing.
- Export Footprint: Presence in over 15 countries, minimizing dependence on a single market.
- Experienced Promoters: Strong leadership with domain expertise, adding stability ahead of the IPO.
Competitors of Anlon Healthcare Ltd.
- Diviβs Laboratories β a global leader in APIs.
- Laurus Labs β strong presence in generic APIs.
- Neuland Laboratories β expertise in custom synthesis and API manufacturing.
- Aarti Drugs β diversified pharmaceutical and chemical portfolio.
Company Financials
Anlon Healthcare Ltd. Financial Information
Anlon Healthcare Ltd. reported an 81% rise in revenue and a 112% jump in PAT between FY24 and FY25, reflecting strong financial growth ahead of the Anlon Healthcare IPO.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 181.30 | 128.00 | 111.55 |
| Total Income | 120.46 | 66.69 | 113.12 |
| Profit After Tax | 20.52 | 9.66 | 5.82 |
| EBITDA | 32.38 | 15.57 | 12.66 |
| Net Worth | 80.42 | 21.03 | 7.37 |
| Reserves and Surplus | 40.57 | 5.03 | -4.63 |
| Total Borrowing | 58.35 | 74.56 | 66.39 |
| Amount in βΉ Crore | |||
Key Performance Indicator (KPI)
The market capitalization of Anlon Healthcare IPO is estimated at βΉ483.68 crore, positioning the company among emerging players in the pharmaceutical sector.
| KPI | Values |
|---|---|
| ROE | 40.45% |
| ROCE | 21.93% |
| Debt/Equity | 0.73 |
| RoNW | 25.51% |
| PAT Margin | 17.06% |
| EBITDA Margin | 26.88% |
| Price to Book Value | 4.51 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 5.15 | 3.86 |
| P/E (x) | 17.67 | 23.57 |
- Note:
- The Pre-IPO EPS is calculated using the pre-issue shareholding as disclosed in the RHP and the latest FY earnings for the period ending March 31, 2025.
- The Post-Issue EPS is derived from the post-issue shareholding and the annualized FY earnings as of March 31, 2025, as mentioned in the RHP.
Objects of the Issue
| S.No. | Objects of the Issue | Expected Amount (in Millions) |
|---|---|---|
| 1 | Funding capital expenditure requirements for Proposed Expansion | 3,071.95 |
| 2 | Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company | 500 |
| 3 | Funding the working capital requirements of the Company | 4,315 |
| 4 | General corporate purposes |
Anlon Healthcare IPO Contact Details
Anlon Healthcare Ltd. Contact Details
- Anlon Healthcare Ltd.
101/102, Silvercoin Complex,
Opp.Crystal Mall,
Kalawad Road,
Rajkot, Gujarat, 360005 - Phone: +91 281 2562538
- Email: cs@anloncro.com
- Website: http://www.anlon.in/
Anlon Healthcare IPO Registrar
- Phone: 04067162222, 04079611000
- Email: ahl.ipo@kfintech.com
- Website: https://ipostatus.kfintech.com/
- Total issue size: βΉ121.03 crore
- Fresh issue: 1.33 crore equity shares
- Offer for Sale (OFS): Nil
- Price band: βΉ86 to βΉ91 per share
- Lot size: 164 shares
- Minimum investment (Retail): βΉ14,104
- Minimum investment (sNII): βΉ2,08,936 for 14 lots (2,296 shares)
- Minimum investment (bNII): βΉ10,14,832 for 68 lots (11,152 shares)
- Allotment Date: September 1, 2025 (Tentative)
- Listing Date: September 3, 2025 (Tentative)
- Exchanges: BSE and NSE
- Revenue FY22: βΉ57.52 million
- Revenue FY23: βΉ113.12 million
- Revenue FY24: βΉ66.69 million
- PAT FY24: βΉ9.66 million (Up 66% from FY23)
- Revenue FY25 Growth: 81% over FY24
- PAT FY25 Growth: 112% over FY24
- Market Capitalization post IPO: βΉ483.68 crore
- Punitkumar R. Rasadia
- Meet Atulkumar Vachhani
- Mamata Punitkumar Rasadia
- Manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates
- Certified with ISO 9001:2015, GMP, and WHO-GMP
- Exports to more than 15 countries worldwide
- Serves pharmaceutical and nutraceutical companies globally
- Operates from its facility in Rajkot, Gujarat